

CURRICULUM VITAE

ERIC C. PETRIE, MD

ASSOCIATE PROFESSOR

DEPARTMENT OF PSYCHIATRY & BEHAVIORAL SCIENCES

UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE

SEATTLE, WASHINGTON

(September 29, 2008)

PERSONAL DATA:

Campus Address: Campus Box 358280/S-182 GRECC
University of Washington
Seattle, WA 98195-8280

Mailing Address: Mail Code S-182 GRECC
Veterans Affairs Puget Sound Health Care System
Seattle Division
1660 South Columbian Way
Seattle, WA 98108

Office Phone: Voice: (206) 277-1683
Fax: (206) 764-2573
Pager: (206) 570-2820
Email: eric.petrie@med.va.gov or epetrie@u.washington.edu

EDUCATION:

1973: Edmonds Community College, Lynwood, Washington.

1974: Everett Community College, Everett, Washington; A.A.S., 12/74

1978: Western Washington University, Bellingham, Washington;
B.A., Magna Cum Laude (Physiological Psychology), 6/78.

1979: National Institute of Mental Health Predoctoral Trainee in Clinical Psychology,
University of Wisconsin, Madison, Wisconsin.

1981: University of Wisconsin, Madison, Wisconsin; M.S. (Clinical Psychology), 8/81.

1982: Medical Student Research Program Summer Trainee, University of Washington School
of Medicine, Seattle, Washington.

1983: March of Dimes Birth Defects Foundation Trainee, Summer Research Program for
Medical Students, University of Washington School of Medicine and Department of
Endocrinology, Veterans Administration Medical Center, Seattle, Washington.

1985: University of Washington School of Medicine, Seattle, Washington; M.D., 6/85.

POSTGRADUATE TRAINING:

Internship

7/85-6/86: University of Washington School of Medicine Affiliated Hospitals, Seattle, Washington.
Combined medicine, neurology, psychiatry transitional program.

Residency

7/86-6/89: Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford,

California.

Fellowship (Research)

7/89-6/90: Schizophrenia Biologic Research Center, Veterans Administration Medical Center, Palo Alto, California.

FACULTY POSITIONS HELD:

7/90-6/94: Acting Instructor, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington.

7/94-6/01: Assistant Professor, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington.

7/01-present: Associate Professor, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington.

HOSPITAL POSITIONS HELD:

7/88-4/89: Staff Psychiatrist (Part-time), Adult Psychiatry Clinic, Kaiser Permanente Medical Center, Santa Clara, California.

8/87-4/90: Contract Psychiatrist (Part-time), Emergency Psychiatric Services, Santa Clara Valley Medical Center, San Jose, California.

7/90-present: Staff Psychiatrist, Veterans Affairs Puget Sound Health Care System (VAPSHCS), Seattle Division, Seattle, Washington.

7/94-6/96: Chief, Inpatient Section, Psychiatry Service, VAPSHCS, Seattle, Washington.

7/97-8/01: Medical Director, Evaluation and Brief Treatment Posttraumatic Stress Disorder Unit (EBTPU), VAPSHCS, Seattle, Washington.

HONORS AND AWARDS:

1978: Graduation Magna Cum Laude, Western Washington University, Bellingham, Washington.

1984: Rock Sleyster Scholar, American Medical Association.

1999: Young Faculty Development Program, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia.

2005: Chief Resident's Award for Dedication to Teaching, Psychiatry Residency Training Program, University of Washington, Seattle, Washington.

BOARD AND OTHER CERTIFICATIONS:

6/86: Diplomate, National Board of Medical Examiners (#315082).

1/92: Board Certified in Psychiatry; American Board of Psychiatry and Neurology (#35256).

11/98-11/03: Certification in Clinical Psychopharmacology; American Society of Clinical Psychopharmacology.

LICENSURE TO PRACTICE:

Medical License - Washington State (#27560)

PROFESSIONAL ORGANIZATIONS:

American Psychiatric Association
Society for Biological Psychiatry

American Society of Clinical Psychopharmacology
Society for Neuroscience

MANUSCRIPT REVIEWS FOR PROFESSIONAL JOURNALS:

10/03: Ad-hoc reviewer, Psychological Medicine.
03/07: Ad-hoc reviewer, General Hospital Psychiatry
11/06-present: Ad-hoc reviewer, Biological Psychiatry
04/08: Ad-hoc reviewer, Dementia and Geriatric Cognitive Disorders

GRANTS AS PRINCIPAL INVESTIGATOR:

Active: Dopamine and choline transporter imaging in DLB & AD. National Institute on Aging Mentored Clinical Scientist Development Award (1K08AG20755-01-A1): 08/15/2005 – 03/30/2010.

Past: Imaging of Brain Noradrenergic Activity in Alzheimer's. Washington State Eagle's Medical Research Grant: 02/05/2004 - 02/04/2005.

Imaging of Brain Noradrenergic Activity in Alzheimer's. Washington State Eagle's Medical Research Grant: 09/01/2003 - 08/31/2004.

Imaging of Brain Noradrenergic Activity in Alzheimer's; University of Washington Alzheimer's Disease Research Center Pilot Grant; 05/01/2003 - 04/30/2004.

Mesolimbic dopamine auto-receptors: regulation and cocaine response; Department of Veterans Affairs Research Advisory Group (RAG) grant: 07/01/1991 - 06/30/1993.

BIBLIOGRAPHY

Manuscripts in Peer-Reviewed Journals:

1. Petrie EC, Tiffany ST, Baker TB, and Dahl JL. Dynorphin (1-13): Analgesia, hypothermia, and cross-tolerance with morphine and beta-endorphin. *Peptides* 3:41-47, 1982.
2. Tiffany ST, Petrie EC, Baker TB, and Dahl JL. Conditioned morphine tolerance in the rat: Absence of a compensatory response and cross-tolerance with stress. *Behavioral Neuroscience* 97:335-353, 1983.
3. Tiffany ST, Petrie EC, Martin EM, and Baker TB. Drug signals enhance morphine tolerance development in hypophysectomized rats. *Psychopharmacology* 79:84-85, 1983.
4. Petrie EC, Matsumoto AM, and Bremner WJ. Modulation of luteinizing hormone pulse amplitude by the frequency of luteinizing hormone-releasing hormone stimulation and by testosterone in castrated, hypothalamic-lesioned rats. *Biology of Reproduction* 38:143-149, 1988.
5. Petrie EC, Faustman WO, Moses JA, Lombrozo L, and Csernansky JG. Correlates of rapid neuroleptic response in male patients with schizophrenia. *Psychiatry Research* 33:171-177, 1990.
6. Petrie EC, Lombrozo L, and Csernansky JG. A microassay for measuring synaptosomal 3H-dopamine and 3H-metabolite release. *Brain Research Bulletin* 25:423-427, 1990.
7. Szot P, Ashleigh EA, Kohen R, Petrie E, Dorsa DM, and Veith R. Norepinephrine transporter mRNA is elevated in the locus coeruleus following short- and long-term desipramine treatment. *Brain Research* 618:308-312, 1993.
8. Petrie EC, Veith RC, and Szot P. Bupropion and desipramine increase dopamine transporter mRNA expression in the ventral tegmental area/substantia nigra of rat brain. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 22:845-856, 1998.

9. Peskind ER, Elrod R, Dobie DJ, Pascualy M, Petrie E, Jensen C, Brodtkin K, Murray S, Veith RC, and Raskind MA. Cerebrospinal fluid epinephrine in Alzheimer's disease and normal aging. *Neuropsychopharmacology* 19:465-471, 1998.
10. Petrie EC, Wilkinson CW, Murray S, Jensen C, Peskind ER, and Raskind MA. Effects of Alzheimer's disease and gender on the hypothalamic-pituitary-adrenal axis response to lumbar puncture stress. *Psychoneuroendocrinology* 24:385-395, 1999.
11. Pascualy M, Petrie EC, Brodtkin K, Peskind ER, and Raskind MA. Effects of advanced aging on plasma catecholamine responses to thermal stress. *Neurobiology of Aging* 20:637-642, 1999.
12. Petrie EC, Peskind ER, Dobie DJ, Veith RC, and Raskind MA. Increased plasma norepinephrine response to yohimbine in elderly men. *Journal of Gerontology; Medical Sciences* 55A:M155-M159, 2000.
13. Raskind MA, Dobie DJ, Kanter E, Petrie EC, and Peskind ER. The alpha-1 adrenergic antagonist prazosin ameliorates combat trauma nightmares in african-american veterans with posttraumatic stress disorder. *Journal of Clinical Psychiatry* 61:129-133, 2000.
14. Pascualy M, Petrie EC, Brodtkin K, Peskind ER, Wilkinson CW, and Raskind MA. Hypothalamic pituitary adrenocortical and sympathetic nervous system responses to the cold pressor test in Alzheimer's disease. *Biological Psychiatry* 48:247-254, 2000.
15. Petrie EC, Peskind ER, Pascualy M, Dobie DJ, Veith RC, and Raskind MA. Plasma catecholamine and cardiovascular responses to physostigmine in Alzheimer's disease and aging. *Psychoneuroendocrinology* 26:147-164, 2001.
16. Wilkinson CW, Petrie EC, Murray SR, Colasurdo EA, Raskind MA, and Peskind ER. Human glucocorticoid feedback inhibition is reduced in older individuals: evening study. *Journal of Clinical Endocrinology and Metabolism* 86:545-550, 2001.
17. Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, and Raskind MA. Increased CSF cortisol in Alzheimer's disease is a function of apolipoprotein E genotype. *Neurology* 56:1094-1098, 2001.
18. Kanter ED, Wilkinson CW, Radant AD, Petrie EC, Dobie DJ, McFall ME, Peskind ER, and Raskind MA. Glucocorticoid feedback sensitivity and adrenocortical responsiveness in PTSD. *Biological Psychiatry* 50:238-245, 2001.
19. Raskind MA, Thompson C, Petrie EC, Dobie DJ, Rein RJ, Hoff DJ, McFall MM, Peskind ER. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. *Journal of Clinical Psychiatry* 63:565-568, 2002.
20. Minoshima S, Foster NL, Petrie EC, Albin RL, Frey KA, Kuhl DE. Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology. *American Journal of Geriatric Psychiatry & Neurology* 15:200-209, 2002.
21. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, Dobie DJ, Hoff D, Rein RJ, Straits-Troster K, Thomas RC, McFall M. Prazosin reduces nightmares and other PTSD symptoms in combat veterans: A placebo-controlled study. *American Journal of Psychiatry* 160:369-371, 2003.
22. Li G, Cherrier MM, Tsuang D, Petrie E, Colasurdo E, Craft S, Schellenberg GD, Wilkinson C, Peskind E, Raskind M. Salivary cortisol and memory function in human aging. *Neurobiology of Aging* 27:1705-1714, 2006.
23. Tsuang DW, Riekse R, Purganan KM, David AC, Montine TJ, Schellenberg GD, Steinbart E, Petrie EC, Bird TD, Leverenz JB. Lewy body pathology in late-onset familial Alzheimer's

disease: a clinicopathologic case series. *Journal of Alzheimer's Disease* 9:235-242, 2006.

24. Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers J, Montine T, Lee VM-Y, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard W, Peskind ER. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. *Journal of Alzheimer's Disease* 10:399-406, 2006.
25. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JCS, Montine TJ. Statin therapy is associated with reduced neuropathologic changes of Alzheimer's disease. *Neurology* 69:878-885, 2007.
26. Vuletic S, Li G, Peskind ER, Kennedy H, Marcovina SM, Leverenz JB, Petrie E, Lee VM-Y, Galasko D, Schellenberg GD, Albers JJ. ApoE highly correlates with APP- and tau-related markers in human CSF. *Journal of Alzheimer's Disease* (in press).

Book Chapters:

1. Petrie EC, Matsumoto AM, Nestor JJ, Vickery BH, Gross KM, Southworth MB, and Bremner WJ. Preclinical studies with LHRH antagonists. In: Zatzuchni GI, Goldsmith A, Spieler JM, Sciarra JJ (Eds.): *Male Contraception: Advances and Future Prospects*. Harper & Row, Philadelphia, 1986, pp 361-368.
2. Minoshima S, Sasaki T, Petrie E. FDG PET Imaging of Dementia: Principles and Clinical Applications. In: Wahl RL (Ed.): *Principles and Practice of PET and PET/CT, 2nd Edition*. Lippincott Williams & Wilkins, Philadelphia (in press).
3. Pascualy M, Wang L, Petrie EC, Murray S, Peskind ER. Management of Agitation in Dementia. In: Halter JB, Ouslander JG, Tinetti M, Woolard N, Studenski S, Asthana S, High K (Eds.): *Hazzard's Geriatric Medicine and Gerontology, 6th Edition*. McGraw-Hill (in press).

Invited Presentations/Symposia:

1. Petrie EC, Pascualy M, Brodtkin K, Peskind ER, Raskind MA. Effects of advanced aging on plasma catecholamine responses to thermal stress. Dementia Symposium, West Coast College of Biological Psychiatry, San Diego, CA, April 14, 2000.
2. Petrie EC. Can neuroimaging aid in the diagnosis of dementia with Lewy bodies? Neuroimaging Symposium, West Coast College of Biological Psychiatry, Seattle, WA, April 4, 2003.
3. Petrie EC. Neuroimaging of brain noradrenergic activity in Alzheimer's disease. University of Washington nuclear medicine technician training program, February 10, 2004.
4. Petrie EC. Treatment of behavioral symptoms in Alzheimer's disease. Third Annual "Sharing the Caring" Luncheon, Katie's Adult Daycare and Respite, Everett, WA, April 27, 2006.
5. Petrie EC. Choosing and using psychotropics in dementia. Continuing Nursing Education Conference on Neuropsychotropic Drug Therapy, University of Washington School of Nursing, Shoreline, WA, June 8, 2007.
6. Petrie EC, Cross DJ, Galasko D, Li G, Raskind MA, Peskind ER, Minoshima S. Voxel-based correlations between cerebral glucose metabolism and cerebrospinal fluid biomarkers in normal controls. Alzheimer's Imaging Consortium, Chicago, IL, July 26, 2008.

Abstracts and Poster Presentations:

1. Petrie EC, Matsumoto AM, and Bremner WJ. Modulation of LH pulse amplitude by the frequency of LHRH stimulation. *Biology of Reproduction* 30(Suppl. 1):71, 1984.
2. Csernansky JG, Petrie EC, Blanchard D, Ott D, and Lammintausta R. Differential effects of

d-medetomidine on 3H-dopamine release from rat striatal and accumbens synaptosomes. Society for Neuroscience Abstracts 14:1094, 1988.

3. **Csernansky JG, Coronel-Bell C, Petrie EC, and Lombrozo L. Changes in mesolimbic dopamine function following hippocampal kindling. Society for Neuroscience Abstracts 15:975, 1989.**
4. **Petrie EC, Faustman WO, Moses JA, Lombrozo L, and Csernansky JG. Characteristics of rapid neuroleptic responders. American College of Neuropsychopharmacology, 28th Annual Meeting, 1989.**
5. **Csernansky JG, Newcomer JW, and Petrie EC. Pharmacological determinants of neuroleptic response. American Psychiatric Association, 144th Annual Meeting, 1991.**
6. **Murburg MM, McFall ME, Petrie E, and Veith RC. Basal sympathoadrenal function in post-traumatic stress disorder. Society for Neuroscience Abstracts 17:146, 1991.**
7. **Veith RC, Szot P, Ashleigh EA, Petrie EC, and Dorsa DM. Acute and chronic desipramine increases norepinephrine carrier m-RNA in the locus coeruleus. Society for Neuroscience Abstracts 18:727, 1992.**
8. **Petrie EC, Szot P, and Veith RC. Bupropion and desipramine increase dopamine transporter mRNA expression in rat brain. Society for Neuroscience Abstracts 20:923, 1994.**
9. **Wilkinson CW, Peskind ER, Murray S, Colasurdo EA, Sikkema C, Rein RJ, Hoff DJ, Wamble M, Petrie EC, and Raskind MA. Age-related deficits in human glucocorticoid feedback inhibition: evening study. International Society for Psychoneuroendocrinology Annual Meeting, 1998.**
10. **Petrie EC, Pascualy M, Brodtkin K, Peskind ER, and Raskind MA. Effects of advanced aging on plasma catecholamine responses to thermal stress. American Aging Society Annual Meeting, Seattle, WA, June, 1999.**
11. **Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CE, and Peskind ER. The alpha-1 adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder. American College of Neuropsychopharmacology Scientific Abstracts, 107, 1999.**
12. **Petrie EC, Pascualy M, Brodtkin K, Peskind ER, and Raskind MA. Effects of advanced aging on plasma catecholamine responses to the cold pressor test. American College of Neuropsychopharmacology Scientific Abstracts, 182, 1999.**
13. **Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD and Raskind MA. Increased cerebrospinal fluid cortisol in Alzheimer's disease is a function of Apolipoprotein E genotype. American College of Neuropsychopharmacology Scientific Abstracts, 240, 2000.**
14. **Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD and Raskind MA. Increased cerebrospinal fluid cortisol in Alzheimer's disease is a function of Apolipoprotein E genotype. Keystone Symposium on Neuronal and Vascular Stress: A New Window on Alzheimer's Disease, Durango, Colorado, January 15-21, 2001.**
15. **Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CC, Peskind ER. The alpha-1 adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder. The 5th International Conference on Progress in Alzheimer's and Parkinson's Disease, 2001.**

16. **Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA. Increased cerebrospinal fluid cortisol in Alzheimer's disease is a function of Apolipoprotein E genotype. The 5th International Conference on Progress in Alzheimer's and Parkinson's Disease, 2001.**
17. **Raskind MA, Peskind ER, Petrie EC, Thompson C, Kanter E, Radant A, Dobie DJ, Hoff DJ, McFall M. Prazosin effects on specific symptoms in chronic combat trauma PTSD. The 19th Annual Meeting of the International Society for Traumatic Stress Studies, Chicago, IL, October, 2003.**
18. **Li G, Cherrier M, Tsuang D, Petrie EC, Colasurdo E, Wilkinson C, Peskind E, Raskind M. Salivary cortisol is associated with cognitive decline in normal elderly. Ninth International Conference on Alzheimer's Disease, Philadelphia, PA, July, 2004.**
19. **Borson S, Manchanda V, Petrie E, Cross D, Lewellen B, Meshberg E, Minoshima S. Cerebral glucose metabolic patterns in patients with suspected Alzheimer's disease and frontotemporal dementia in a geriatric clinic. Tenth International Conference on Alzheimer's Disease, Madrid, Spain, July, 2006.**
20. **Peskind ER, Li G, Petrie EC, Leverenz J, Raskind MA, Galasko D. Gender, age, and APOE genotype effects on CSF Abeta-42 in cognitively normal adults. Society of Biological Psychiatry 62nd Annual Meeting, San Diego, CA, May, 2007.**
21. **Petrie E, Cross D, Larson E, Anzai Y, Meshberg E, Maravilla K, Stevenson J, Lewellen B, Minoshima S. What is the relationship between regional cortical metabolic activity and subcortical microvascular ischemia? A quantitative FDG PET and MRI mapping analysis. Society for Nuclear Medicine 54th Annual Meeting, Washington DC, June, 2007.**
22. **Tozer KR, Cross DJ, Petrie EC, Stevenson J, Anzai Y, Maravilla KR, Peskind ER, Minoshima S. Reduction in Cortical Metabolism and Cerebral White Matter Integrity in Aging Brains: FDG-PET and MR-DTI Analysis. American Society of Neuroradiology 46th Annual Meeting, New Orleans, LA, May, 2008.**
23. **Petrie EC, Cross DJ, Galasko D, Li G, Raskind MA, Peskind ER, Minoshima S. Voxel-based correlations between cerebral glucose metabolism and cerebrospinal fluid biomarkers in normal controls. 11th International Conference on Alzheimer's Disease, Chicago, IL, July, 2008.**
24. **Wang LY, Petrie EC, Rohde K, Hart KL, Hoff DJ, Shofer JB, Raskind MA, Peskind ER. Prazosin for treatment of disruptive agitation in Alzheimer's disease. 11th International Conference on Alzheimer's Disease, Chicago, IL, July, 2008.**
25. **Li G, Galasko DR, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Petrie EC, Leverenz J, Shofer JB, Schellenberg GD, Cottrell B, Peskind ER. Age- and APOE-related cerebrospinal fluid Alzheimer's disease biomarker changes in normal controls. 11th International Conference on Alzheimer's Disease, Chicago, IL, July, 2008.**
26. **Peskind ER, Li G, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Petrie EC, Leverenz J, Schellenberg GD, Cottrell B, Galasko DR. Cerebrospinal fluid biomarkers distinguish mild Alzheimer's disease and mild cognitive impairment from cognitively healthy aging. 11th International Conference on Alzheimer's Disease, Chicago, IL, July, 2008.**
27. **Raskind MA, Petrie EC, Wilkinson CW, Li G, Chi P, Galasko DR, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Wang LY, Leverenz JB, Schellenberg GD, Peskind ER. Cerebrospinal fluid norepinephrine increases with aging, Alzheimer's disease and APOE4 genotype. 11th International Conference on Alzheimer's Disease, Chicago, IL, July, 2008.**